ATL146e decreases pulmonary leukocytosis in NY1DD mice by activating adenosine A2ARs
| Cells (105) . | (a) C57BL/6 vehicle (n = 8) . | (b) C67BL/6 ATL146e (n = 4) . | (c) NY1DD vehicle (n = 8) . | (d) NY1DD ATL146e (n = 8) . | (e) NY1DD- A2AR−/− vehicle (n = 6) . | (f) NY1DD-A2AR−/− ATL146e (n = 6) . |
|---|---|---|---|---|---|---|
| iNKT | 0.19 (0.02) | 0.13 (0.02) | 0.5 (0.04)* | 0.29 (0.03)** | 0.58 (0.05) | 0.55 (0.09) |
| NK | 1.7 (0.2) | 1.8 (0.3) | 4.2 (0.5)* | 1.2 (0.3)** | 4.0 (0.5) | 4.1 (0.4) |
| CD4 | 1.0 (0.09) | 1.3 (0.4) | 3.0 (0.2)* | 1.0 (0.2)** | 3.3 (0.8) | 3.2 (0.7) |
| CD8 | 1.1 (0.1) | 1.3 (0.2) | 2.3 (0.4)* | 0.9 (0.1)** | 2.8 (0.4) | 2.9 (0.3) |
| PMNs | 0.3 (0.07) | 0.3 (0.1) | 2.3 (0.3)* | 0.4 (0.1)** | 2.9 (0.7) | 3.1 (0.5) |
| Cells (105) . | (a) C57BL/6 vehicle (n = 8) . | (b) C67BL/6 ATL146e (n = 4) . | (c) NY1DD vehicle (n = 8) . | (d) NY1DD ATL146e (n = 8) . | (e) NY1DD- A2AR−/− vehicle (n = 6) . | (f) NY1DD-A2AR−/− ATL146e (n = 6) . |
|---|---|---|---|---|---|---|
| iNKT | 0.19 (0.02) | 0.13 (0.02) | 0.5 (0.04)* | 0.29 (0.03)** | 0.58 (0.05) | 0.55 (0.09) |
| NK | 1.7 (0.2) | 1.8 (0.3) | 4.2 (0.5)* | 1.2 (0.3)** | 4.0 (0.5) | 4.1 (0.4) |
| CD4 | 1.0 (0.09) | 1.3 (0.4) | 3.0 (0.2)* | 1.0 (0.2)** | 3.3 (0.8) | 3.2 (0.7) |
| CD8 | 1.1 (0.1) | 1.3 (0.2) | 2.3 (0.4)* | 0.9 (0.1)** | 2.8 (0.4) | 2.9 (0.3) |
| PMNs | 0.3 (0.07) | 0.3 (0.1) | 2.3 (0.3)* | 0.4 (0.1)** | 2.9 (0.7) | 3.1 (0.5) |
Treatment of C57BL/6 mice with ATL146e (10 ng/kg/minute) has no effect on pulmonary leukocyte numbers (b vs a). In NY1DD mice, pulmonary leukocytes are elevated (c vs a) and treatment with ATL146e counteracts this effect (d vs c). Deletion of the A2AR from NY1DD mice eliminates the effect of ATL146e to reduce leukocyte numbers (f vs e). Data represents means ± SEM and were analyzed by 1-way ANOVA with Neuman-Keuls posttesting.
P < .05 (a vs c).
P < .05 (c vs d).